| Entries |
| Document | Title | Date |
|---|
| 20100004244 | USE OF CB2 RECEPTOR AGONISTS FOR PROMOTING NEUROGENESIS - The present invention relates to ligands of the peripheral cannabinoid receptor CB | 01-07-2010 |
| 20090281105 | RADIOTHERAPY ENHANCER - The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. A radiotherapy enhancer comprising (A) tegafur and (B) gimeracil. | 11-12-2009 |
| 20090012091 | Oximide derivatives and their therapeutical application - The present invention relates to a compound represented as the following Formula (I) and a pharmaceutical composition thereof | 01-08-2009 |
| 20110281875 | Inhibitors of IAP - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I). | 11-17-2011 |
| 20100137317 | 1,2-Disubstituted Heterocyclic Compounds - 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms. | 06-03-2010 |
| 20080214548 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors - The invention relates to compounds of the formula I | 09-04-2008 |
| 20090137594 | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments - The present invention relates to pentafluorosulphanyl-substituted compounds, methods for their production, medicaments containing such compounds and the use of such compounds for producing medicaments. | 05-28-2009 |
| 20100249136 | ORGANIC COMPOUNDS - The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of Parkinson's Disease and associated disorders | 09-30-2010 |
| 20080306073 | Antitumor Effect Potentiator, Antitumor Preparation, and Method for Treating Cancer - An antitumor effect fortifier comprising as an active ingredient an effective amount of platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) so as to enhance the antitumor activity of antitumor agent containing a therapeutically effective amount of tegafur, an amount, effective for the enhancement of antitumor effect, of gimeracil and an amount, effective for the suppression of side effects, of oteracil potassium; and a relevant antitumor agent. Further, there is provided a method of therapy for cancer, characterized in that an amount, effective for the enhancement of antitumor effect, of platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) is concomitantly administered to a mammal. Still further, there is provided an antitumor agent consisting of a pharmaceutical preparation form composed of at least two separate preparations containing efficacious ingredients consisting of tegafur, gimeracil, oteracil potassium and platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) each alone or in an arbitrary combination, or a pharmaceutical preparation form constituted of a single preparation containing all the efficacious ingredients. Still further, there is provided a relevant kit. | 12-11-2008 |
| 20090105260 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor - An IR spectroscopic technique provides methods for measuring the irritation potential of a formulation and to assess the ability of molecules to enhance the permeability of substances into and through skin using samples comprising stratum corneum. Molecules are screened for their performance as chemical penetration enhancers using a unique in silico procedure that may be applied iteratively in an attempt to generate molecules showing successively higher performance. Both the irritation potential and the ability of the molecule to enhance penetration are considered in the in silico approach. The invention provides specific molecules that may be used in topical or transdermal formulations to improve the delivery of actives. The structures of compounds of the invention include: Formulas (I), (II), (III), (IV), (V), (IV) and analogs thereof. | 04-23-2009 |
| 20080318958 | New utilities of tricyclic compounds - Pharmaceutical compositions for enhancing the expression of apoAI are provided, which are used as medicaments for treatment of cardiovascular diseases on the basis of improving the functions of HDL. | 12-25-2008 |
| 20080261987 | SUBSTITUTED PIPERAZINES - Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists. | 10-23-2008 |
| 20090247530 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES - The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions. | 10-01-2009 |
| 20100227866 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF - [Problems] To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). | 09-09-2010 |
| 20090325964 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression - The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula I: | 12-31-2009 |
| 20090318453 | POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR GASTRIC CANCER - The invention provides a method for treatment of gastric cancer, which method is a postoperative adjuvant chemotherapy for gastric cancer, comprising orally administering, to a patient with gastric cancer in stage II, IIIA, or IIIB in a classification of the stage of gastric cancer, a pharmaceutical composition containing Tegafur, Gimeracil, and Oteracil potassium at a molar ratio of 1:0.4:1, at a dose of 50 to 150 mg/day as Tegafur dose and according to an administration schedule including, from within 45 days after a surgical operation of gastric cancer, drug administration for 28 consecutive days, followed by a rest period of 7 to 14 consecutive days. | 12-24-2009 |
| 20100305132 | GLUTARALDEHYDE BASED BIOCIDAL COMPOSITIONS AND METHODS OF USE - Provided are biocidal compositions comprising glutaraldehyde and a compound selected from the group consisting of 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane; tris(hydroxymethyl)-nitromethane; and a hexahydrotriazine compound. The compositions are useful for controlling microorganisms in aqueous or water-containing systems. | 12-02-2010 |
| 20110021530 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS - Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human, including administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R | 01-27-2011 |
| 20110039854 | LINEAR AND CYCLIC GUANIDINE DERIVATIVES, METHOD OF PREPARATION AND USES THEREOF - The present invention relates to linear and cyclic guanidine derivatives, method of preparation and uses thereof, pharmaceutical compositions to be used as antifungal agents, in particular against | 02-17-2011 |
| 20110046140 | AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS - Biocidal compositions and their use in aqueous media, such as metalworking fluids, the compositions comprising a biocidal agent; and a non-biocidal primary amino alcohol compound of the formula (I): wherein R | 02-24-2011 |
| 20090312330 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE - An isoxazoline-substituted benzamide compound of formula (1) or a salt thereof: | 12-17-2009 |
| 20090203700 | Azolylmethyloxiranes, Their Use for Controlling Phytopathogenic Fungi, and Compositions Comprising Them - The present invention relates to azolylmethyloxiranes of the general formula I | 08-13-2009 |
| 20080221107 | Therapeutic Agents - Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them. | 09-11-2008 |
| 20110136810 | ANTITUMOR AGENT, KIT AND METHOD OF TREATING CANCER - Disclosed are an antitumor preparation comprising a combination of (1) a combination drug of tegafur/gimeracil/oteracil potassium, (2) at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof, and (3) cis-oxalate(1R,2R-diaminocyclohexane)platinum(II); a kit comprising a combination of pharmaceutical compositions for treating cancer in a mammal, comprising: (a) a combination drug of tegafur/gimeracil/oteracil potassium in a therapeutically effective amount; (b) a composition containing at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof in an amount effective for enhancing antitumor effects, and (c) a composition containing cis-oxalate(1R,2R-diaminocyclohexane)platinum(II) in an amount effective for enhancing antitumor effects; and a method for treating cancer. | 06-09-2011 |
| 20080255125 | Topically Applied Medicament for Animals - The invention relates to pharmaceutical preparations, which are applied to the pelt or skin of animals and are then absorbed by the latter orally. | 10-16-2008 |
| 20120015948 | TABLET COMPOSITION - A water soluble effervescent disinfecting tablet comprises a chlorinated isocyanurate such as anhydrous sodium dichloroisocyanurate. The tablet also comprises an alkali metal bicarbonate such as sodium bicarbonate, an aliphatic carboxyl acid such as adipidic acid, and a dessicant base such as sodium carbonate. The tablet contains a masking agent, especially isoamyl acetate and/or L-methone in an amount to mask taste and/or odour characteristics of the chlorinated isocyanurate. | 01-19-2012 |
| 20090099188 | MICROBICIDAL COMPOSITION BASED ON FORMALDEHYDE DONOR COMPOUNDS AND ANTIOXIDANTS - A microbicidal composition and its method of use for preserving technical products such as fuels and lubricants. The composition is made up of at least one formaldehyde donor compound and at least one antioxidant. The antioxidant is either a gallic ester, a phenol derivative, a L-ascorbic acid, including salts and derivatives thereof, a tocopherol or one of its associated derivatives. | 04-16-2009 |
| 20120059009 | ANTI-TUMOR AGENT CONTAINING TEGAFUR-GIMERACIL-OTERACIL POTASSIUM COMBINATION DRUG AND OXALIPLATIN - To provide a novel combination therapy which exhibits remarkable anti-tumor effect. | 03-08-2012 |
| 20120108593 | Extreme temperature aqueous decontamination composition - An extreme temperature decontamination composition such as a solution for destroying microorganisms, chemical warfare and bioterrorism agents is utilized that generally does not freeze at low temperatures down to about minus 25° F. and also has no significant evaporation or decomposition at temperatures up to about 120° F. The solution is effective against nerve agents and vesicants such as VX and HD, and various biological agents. The composition comprises a metallic salt of dichloroisocyanuric acid or dibromoisocyanuric acid, an aqueous solvent system comprising polar compounds such as water and an alkyl glycol, and a quasi hydrophilic compound. The composition can be formulated as a one part system wherein all components are blended together. | 05-03-2012 |
| 20090258876 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT - Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have high affinity for 5-HT | 10-15-2009 |
| 20100093736 | AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS - Biocidal compositions and their use in aqueous media, such as metalworking fluids, the compositions comprising a biocidal agent; and a non-biocidal primary amino alcohol compound of the formula (I); wherein R | 04-15-2010 |
| 20120238578 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS - The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 09-20-2012 |
| 20120101102 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF CHEMOTHERAPY ON RENAL CELL CANCER - The present invention developed a novel antitumor agent for renal cell carcinoma that cannot be fully treated by the existing therapies. The present invention provides an antitumor agent comprising a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent therapeutic effect in renal cell carcinoma patients that is superior to that of the existing therapies, by way of selecting the patients based on thymidylate synthase. | 04-26-2012 |
